Parkinson’s drug from market

We believe that dopamine agonists are a valuable part of the arsenal in the treatment of Parkinson’s disease, said John Feeney III, MD, acting deputy director of the Division of Neurology Products of the FDA’s center for medical evaluation and research.Diagnosis of children including cystic fibrosis , diabetes, arthritis, eczema, rashes and asthma. Children and their parents were questioned about the child’s social activities, behavior, self-esteem, physical limitations and pain.

The FDA approved Permax in 1988 for use with another drug, levodopa to treat Parkinson’s disease.

The basic conclusion we draw is that pergolide had not shown a benefit or more likely one of the other therapies for Parkinson’s disease, says Temple.

The FDA is trying to reach an agreement with officials of pergolide to keep the drug available in a few restrictions for people who find that simply can not be without drugs, said Temple.

Patients should not stop taking pergolide instantly. Should talk with your doctor first, said Robert Temple, MD, medical director of policy for the FDA Center for Drug Evaluation and Research.

Pergolide from the market will not disappear immediately. It will be removed to allow people to plan other treatments.

Permax belongs to a class of drugs called dopamine agonists. The action today does not affect any other dopamine agonists or other drugs against Alzheimer’s disease.

Permax is marketed by Valeant Pharmaceuticals International. Generic Pergolide is marketed by Par Pharmaceutical Companies and Teva Pharmaceuticals.

WebMD report on these studies in January 2007, when studies appeared in the New England Journal of Medicine. Advice for patients

A 12 000 people across the United States have received prescriptions for pergolide, in 2006, according to the FDA. Temple said the drug’s use had declined in the light of the risks of heart valve.

This view was reinforced in a black box warning – the strongest warning the FDA – in 2006, based on European studies mentioned above.

I would say that there was enough consensus that the time had run out for this drug, says Temple.

The FDA today announced that the Parkinson’s drug Permax and its generic versions have voluntarily withdrawn from the U.S. market because of the risk of serious damage to heart valves.

Temple said the FDA has requested the removal of pergolide products from the market and producers negotiated.

Reports of heart valve leakage pergolide users emerged in 2002, and a warning about the problems of the heart valves went on the label of the drug in 2003.

But there are other dopamine agonists, and there is no alternative, even more, there are other therapies available for patients with Parkinson’s disease, said Feeney.

Pergolide History